Crohn’s Disease Overview

What is Crohn’s Disease?

Crohn’s disease is a form of Inflammatory Bowel Disease (IBD) characterized by inflammation in the digestive tract. This condition can impact various sections of the gastrointestinal tract, including the small intestine, large intestine, and colon.

Common Symptoms

The primary symptoms of Crohn’s disease include chronic diarrhea and abdominal pain. Additional symptoms may encompass fatigue, fever, blood in the stool, and weight loss.

Causes and Risk Factors

While the exact causes of Crohn’s disease remain unclear, it is believed that the immune system plays a significant role in its development. Genetic factors also contribute, as individuals with a family history of the disease are at higher risk. Other risk factors include age, a history of smoking, and the use of non-steroidal anti-inflammatory medications.

Diagnosis of Crohn’s Disease

Diagnostic Process

To diagnose Crohn’s disease, healthcare providers gather detailed medical histories and conduct various medical tests. These may include blood tests, colonoscopy, CT scans, or MRI.

Treatment Options for Crohn’s Disease

Treatment Goals

The primary objective of Crohn’s disease treatment is to reduce inflammation that leads to pain and other symptoms. Achieving long-term remission is possible with effective treatment, which can minimize serious long-term complications associated with the disease.

Medication Considerations

Treatment plans may vary depending on the severity and location of the disease. Certain medications may be contraindicated based on other medical conditions or during pregnancy.

Corticosteroids

Corticosteroids are often the first-line treatment for Crohn’s disease. Clinical studies indicate that oral corticosteroids are effective in inducing remission compared to placebo. However, prolonged use is not recommended due to potential side effects.

Budesonide

Budesonide is an oral medication used to lessen inflammation, typically for patients with mild to moderate Crohn’s disease. While it has fewer side effects than other corticosteroids, possible adverse effects include headache, nausea, vomiting, diarrhea, and fatigue. Serious side effects may include immune system suppression and severe allergic reactions.

Prednisone

For individuals who do not respond to budesonide, prednisone may be prescribed. Side effects can include weight gain, elevated blood pressure, headache, nausea, vomiting, and muscle weakness, with serious risks such as stomach ulcers or cardiovascular issues.

Immunosuppressants

Immunosuppressants work by reducing immune activity that contributes to inflammation. These medications are typically used to maintain remission in Crohn’s disease patients.

Azathioprine and Mercaptopurine

Azathioprine and mercaptopurine are often utilized to decrease steroid use. Although clinical trials have shown they may not be more effective than placebo, they are frequently combined with other treatments to lower steroid dependence.

Methotrexate

Methotrexate is another option for patients who do not respond well to other treatments, requiring close monitoring for side effects.

Biologics

Biologics, including antibodies, are approved for treating Crohn’s disease but can lead to significant side effects, including serious infections and increased cancer risk.

TNF-Inhibitors

TNF inhibitors neutralize tumor necrosis factor (TNF), an immune system protein. These drugs, such as infliximab, adalimumab, and certolizumab, are effective in inducing and maintaining remission in patients unresponsive to other treatments.

Anti-Integrins

Anti-integrin drugs, including natalizumab and vedolizumab, target integrins to treat Crohn’s disease. While natalizumab has significant side effects, vedolizumab appears to be effective with fewer adverse effects.

Ustekinumab

Ustekinumab, a monoclonal antibody that inhibits interleukin-12 and interleukin-23, is now approved for Crohn’s disease treatment. It has shown efficacy in inducing and maintaining remission in patients who have previously failed TNF inhibitor therapy. However, it carries risks of significant infections, including tuberculosis.

References

1. Lichtenstein, Gary R MD, FACG et al. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. American Journal of Gastroenterology, April 2018.
2. Clinical Practice Guidelines. Journal of the Canadian Association of Gastroenterology, 2019.
3. Gajendran, Mahesh et al. A comprehensive review and update on Crohn’s disease. Disease-a-Month, 2018.
4. Veauthier B, Hornecker JR. Crohn’s Disease: Diagnosis and Management. Am Fam Physician, 2018.
5. Shi, H. Y., & Ng, S. C. The state of the art on treatment of Crohn’s disease. Journal of gastroenterology, 2018.
6. Lamb, Y.N., Duggan, S.T. Ustekinumab: A Review in Moderate to Severe Crohn’s Disease. Drugs, 2017.